CN100534990C - 吡咯烷酮羧酰胺 - Google Patents

吡咯烷酮羧酰胺 Download PDF

Info

Publication number
CN100534990C
CN100534990C CNB028265483A CN02826548A CN100534990C CN 100534990 C CN100534990 C CN 100534990C CN B028265483 A CNB028265483 A CN B028265483A CN 02826548 A CN02826548 A CN 02826548A CN 100534990 C CN100534990 C CN 100534990C
Authority
CN
China
Prior art keywords
phenyl
oxo
carboxylic acid
racemize
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028265483A
Other languages
English (en)
Chinese (zh)
Other versions
CN1610678A (zh
Inventor
马库斯·伊斯勒
托马斯·吉勒
冈特·施瓦姆
马蒂亚斯·施特格
库尔特·希尔珀特
奥利弗·瓦尔德奈尔
福尔克尔·布罗伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1610678A publication Critical patent/CN1610678A/zh
Application granted granted Critical
Publication of CN100534990C publication Critical patent/CN100534990C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028265483A 2001-12-31 2002-12-27 吡咯烷酮羧酰胺 Expired - Fee Related CN100534990C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH23812001 2001-12-31
CH2381/01 2001-12-31
CH2381/2001 2001-12-31
CH0200429 2002-08-05
CHPCT/CH02/00429 2002-08-05

Publications (2)

Publication Number Publication Date
CN1610678A CN1610678A (zh) 2005-04-27
CN100534990C true CN100534990C (zh) 2009-09-02

Family

ID=25705687

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028265483A Expired - Fee Related CN100534990C (zh) 2001-12-31 2002-12-27 吡咯烷酮羧酰胺

Country Status (8)

Country Link
EP (1) EP1463724A1 (https=)
JP (1) JP2005521651A (https=)
KR (1) KR20040072697A (https=)
CN (1) CN100534990C (https=)
AU (1) AU2002350366A1 (https=)
CA (1) CA2471620A1 (https=)
MX (1) MXPA04006458A (https=)
WO (1) WO2003059905A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
JP4726243B2 (ja) * 2005-08-09 2011-07-20 第一三共株式会社 新規セルコスポラミド誘導体
WO2007018193A1 (ja) * 2005-08-09 2007-02-15 Daiichi Sankyo Company, Limited 新規セルコスポラミド誘導体
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2480531B1 (en) * 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
EP3126346B1 (en) * 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers
EP3194365A4 (en) * 2014-09-14 2018-04-25 Nanosynthons LLC Pyrrolidone derivatives, oligomers and polymers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001085714A1 (en) * 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB856452A (en) * 1957-06-27 1960-12-14 Bayer Ag Protective agents against textile pests, mould and bacteria
US5281612A (en) * 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
DE69025418T2 (de) * 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001085714A1 (en) * 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor

Also Published As

Publication number Publication date
JP2005521651A (ja) 2005-07-21
WO2003059905A1 (de) 2003-07-24
EP1463724A1 (de) 2004-10-06
CN1610678A (zh) 2005-04-27
AU2002350366A1 (en) 2003-07-30
MXPA04006458A (es) 2004-10-04
KR20040072697A (ko) 2004-08-18
CA2471620A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
CN100534990C (zh) 吡咯烷酮羧酰胺
AU2008206759B2 (en) Nicotinic acetylcholine receptor modulators
CN101679239B (zh) 组蛋白脱乙酰酶抑制剂
ES2345662T3 (es) Derivados de acido indol-1-il-acetico.
KR100979577B1 (ko) 2형 진성 당뇨병의 치료를 위한11-베타-하이드록시스테로이드 탈수소효소의 억제제로서1-설폰일-피페리딘-3-카복실산 아마이드 유도체
JPH08508738A (ja) ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体
JP2007510702A (ja) 代謝性疾患の処置に有用な１１−β−ＨＳＤ１阻害剤としてのＮ−アシル化−３−（ベンゾイル）−ピロリジン
KR101171507B1 (ko) 신규 피페라진 아마이드 유도체
TW200944526A (en) Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP2001516356A (ja) プロテインキナーゼ阻害剤として有用な置換２−アニリノピリミジン
NO324792B1 (no) Farmasoytisk aktive sulfonamidderivater
JPWO2008059854A1 (ja) ピペリジン誘導体またはその塩
CN101018774A (zh) α7烟碱性乙酰胆碱受体的调节剂和其治疗用途
TWI466866B (zh) 被取代之環己基二胺
JP2006517566A (ja) ピペラジン−２−カルボキサミド誘導体
US20040152692A1 (en) Pyrrolidine sulfonamides
US5319096A (en) (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
JP2021515787A (ja) アミノ−ベンゾイソチアゾール及びアミノ−ベンゾイソチアジアゾールのアミド化合物
JP2009519968A (ja) 化学物質
US7067549B2 (en) Pyrrolidone carboxamides
JP2000504342A (ja) ニューロキニンアンタゴニストとしてのピペラジノ誘導体
KR20080089413A (ko) 카나비노이드 ｃｂ1 수용체 조절자로서의4,5-디하이드로-(1ｈ)-피라졸 유도체
JP5142152B2 (ja) ４，５−ジアリールピロール誘導体、この調製方法および治療におけるこの使用
US20100227856A1 (en) Novel compounds
JP2008538357A (ja) 薬学的に活性なジアゼパン

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090902

Termination date: 20100127